IceCure Stock Surges After 70% ProSense Install Increase

IceCure Medical Ltd. (NASDAQ:ICCM) shares are soaring Wednesday after the company reported a 70% jump in its U.S. commercial install base for ProSense, its breast cancer cryoablation system. Here’s what you should know.

IceCure Medical stock is showing exceptional strength. What’s fueling ICCM momentum?

Install Base Expands 70% After FDA Authorization
IceCure announced that its active United States install base for ProSense grew 70% following FDA marketing authorization in October 2025. The company said the increase reflects faster commercial adoption, rising physician demand and broader expansion of its United States presence.
IceCure has continued placing new ProSense systems in clinics and hospitals across the country. Procedures are now being performed in major metropolitan areas suc